Document is current
Any future updates will be listed below
-
Authors
Aleem, Samia http://orcid.org/0000-0003-0291-7608
Benjamin, Daniel K. Jr
Burns, Charles M. http://orcid.org/0000-0002-4183-0532
Duncan, Jacob
Melaku, Kalkidan
Norbekov, Abdulaziz
Graham, Bethany
Mantena, Sriya
Ladipo, Tomi
Jung, Ayan
Zimmerman, Kanecia O.
Clark, Reese H. http://orcid.org/0000-0002-7363-4640
Greenberg, Rachel G. http://orcid.org/0000-0003-4156-8543
- License Information
-
More Information
Article History
Received: 26 January 2024
Revised: 3 July 2024
Accepted: 16 July 2024
First Online: 26 July 2024
Competing interests
: DKB reports consultancy for Allergan, Melinta Therapeutics, and Sun Pharma Advanced Research Co. KOZ reports funding from the National Institutes of Health (NIH) and US Food and Drug Administration (FDA). RGG reports support from industry for research services (). All other authors report no conflicts of interest.
: This study was approved by the Duke University Institutional Review Board as exempt research. This study was performed in accordance with the Declaration of Helsinki.
